Gentian Diagnostics ASA

OB:GENT Stock Report

Market Cap: NOK 616.9m

Gentian Diagnostics Future Growth

Future criteria checks 5/6

Gentian Diagnostics is forecast to grow earnings and revenue by 63.5% and 25.7% per annum respectively while EPS is expected to grow by 103.3% per annum.

Key information

63.5%

Earnings growth rate

103.3%

EPS growth rate

Medical Equipment earnings growth18.8%
Revenue growth rate25.7%
Future return on equityn/a
Analyst coverage

Low

Last updated14 Nov 2024

Recent future growth updates

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14
Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Recent updates

Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Jun 29
Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14
Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Oct 28
Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

May 11
We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

Mar 20
Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Feb 21
What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

Jan 17
Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?

Dec 14
Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?

Earnings and Revenue Growth Forecasts

OB:GENT - Analysts future estimates and past financials data (NOK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202626132N/AN/A1
12/31/20252012321311
12/31/2024151168181
9/30/202415422231N/A
6/30/2024153-2513N/A
3/31/2024149-61521N/A
12/31/2023142-111115N/A
9/30/2023129-5-12-7N/A
6/30/2023122-14-60N/A
3/31/2023120-18-19-6N/A
12/31/2022112-24-29-14N/A
9/30/2022106-29-34-19N/A
6/30/2022100-26-43-26N/A
3/31/202299-26-42-29N/A
12/31/2021100-25-40-27N/A
9/30/202199-19-24-9N/A
6/30/202196-19-27-16N/A
3/31/202184-17-20-12N/A
12/31/202079-17-19-13N/A
9/30/202072-21-16-13N/A
6/30/202070-19-16-13N/A
3/31/202062-38-28-25N/A
12/31/201955-40-26-21N/A
9/30/201944-46-25-20N/A
6/30/201948-41-22-17N/A
3/31/201947-23-18-12N/A
12/31/201846-20-17-11N/A
9/30/201851-12-23-18N/A
6/30/201841-16N/A-19N/A
3/31/201840-14N/A-16N/A
12/31/201735-15N/A-19N/A
9/30/201734-13N/A-19N/A
6/30/201732-12N/A-18N/A
3/31/201730-13N/A-16N/A
12/31/201631-9N/A-8N/A
12/31/201526-3N/A-5N/A
12/31/201425-3N/A-2N/A
12/31/2013231N/A2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GENT's forecast earnings growth (63.5% per year) is above the savings rate (2.4%).

Earnings vs Market: GENT's earnings (63.5% per year) are forecast to grow faster than the Norwegian market (9.5% per year).

High Growth Earnings: GENT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GENT's revenue (25.7% per year) is forecast to grow faster than the Norwegian market (2.2% per year).

High Growth Revenue: GENT's revenue (25.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GENT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 02:07
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gentian Diagnostics ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinssonDNB Markets
Geir HolomDNB Markets